Determining the presence of androgen receptor splice variant 7 (AR-V7) protein in circulating tumour cells (CTC) improves the clinical decision-making process when choosing between an androgen receptor signalling inhibitor or a taxane at the start of second or greater line of therapy in men with progressing metastatic castration-resistant prostate cancer, a study has shown.
Patients with newly diagnosed multiple myeloma (MM) with suboptimal response to an immunomodulatory triplet regimen benefited from a response-adapted intensification regimen with cyclophosphamide, bortezomib, and dexamethasone (CVD), leading to improved depth of response (DpR) and progression-free survival (PFS), according to outcomes from the Myeloma XI trial.
The reduced incidence of breast cancer with 5-year prophylaxis with the aromatase inhibitor anastrozole among women at high risk of the disease persists even after anastrozole cessation, suggests long-term results of the IBIS-II* trial presented at SABCS 2019.
The addition of tucatinib to a trastuzumab-capecitabine regimen improved progression-free survival (PFS) in patients with HER2+ metastatic breast cancer (MBC) previously treated with multiple HER2-targeted agents, according to the HER2CLIMB* study presented at SABCS** 2019. Additionally, this improved PFS was also noted in patients with brain metastases.
Olanzapine 5 mg, used in combination with standard triplet antiemetic therapy, is effective in controlling chemotherapy-induced nausea and vomiting (CINV) and associated with a low rate of grade 3 somnolence, according to results of a phase III trial conducted in Japan.
Older patients and those with haemato-oncology conditions are less likely than surgical patients to be referred to infectious disease (ID) physicians within 48 hours of hospital admission. Furthermore, they appear to be more likely to require antibiotic stewardship programmes (ASP) due to inappropriate type or duration of antibiotic therapy despite ID consultations, a retrospective cross-sectional study from Singapore showed.
A new Labyrinth microfluidic device, coupled with three clinically validated markers, isolates and quantifies circulating tumour cells (CTCs) from blood samples of patients with hepatocellular carcinoma (HCC), reports a study.
Adding the oral HER2-targeted tyrosine kinase inhibitor (TKI) tucatinib to trastuzumab-capecitabine combination therapy significantly improves progression-free survival (PFS) and overall survival (OS) in patients with heavily pretreated HER2-positive metastatic breast cancer, including those with brain metastases, results of the HER2CLIMB trial have shown.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.